Notice: This company has been marked as potentially delisted and may not be actively trading. Antares Pharma (ATRS) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Best Healthcare Penny StocksSeptember 18, 2024 | benzinga.comAntares Vision SpA AVJanuary 24, 2024 | morningstar.comAntares Vision Share Price (AV.MI)December 7, 2023 | lse.co.ukAprea Therapeutics’ Promising Clinical Data and Distinctive Drug Profile: An Analysis of Jason McCarthy’s Buy RatingOctober 19, 2023 | markets.businessinsider.comAntares Reaches New 52-Week High (AIS)September 3, 2023 | thestreet.comAntares Vision SpA (ANV)August 2, 2023 | investing.comCOP Syringes Market Competitive Situation By 2030April 27, 2023 | marketwatch.comPharma Track and Trace Solutions Market Trends By 2031April 6, 2023 | marketwatch.comTransdermal Patch Drug Delivery System Market Size, Share, Demand, Opportunity, Outlook, Trends, Revenue, and Future Growth 2027March 28, 2023 | marketwatch.comDrug Transport Technology Market Top Players By 2031March 27, 2023 | marketwatch.comDrug Delivery Technology Market 2023 Size and Forecast to 2030March 25, 2023 | marketwatch.comPharma Track and Trace Solutions Market Forecast 2023 To 2029 Size, Global Predictive AnalyticsMarch 4, 2023 | marketwatch.comGlobal Genitourinary Drugs Market Report 2022 to 2027: Featuring Allergan, Antares Pharma, Bayer and Novartis Among OthersFebruary 17, 2023 | yahoo.comPharma Track and Trace Solutions Market : Analysis, Forecast, Size, New Trends and Insights, Update, COVID-19 ImpactJanuary 4, 2023 | marketwatch.comPharma Track and Trace Solutions Market 2022 : Incredible Possibilities, Growth Analysis and Forecast To 2028December 16, 2022 | marketwatch.comDrug Delivery Technology Market Global Demand, Opportunities, Trends, Analysis and Forecast to 2030December 1, 2022 | marketwatch.comPharmaceutical Drug Delivery Global Market Report 2022September 14, 2022 | yahoo.comPharma Track and Trace Solutions Market Report Detailed Market Analysis and Forecasts 2022 To 2028 | 112 Pages ReportAugust 20, 2022 | marketwatch.comLooking Into Antares Pharma's Return On Invested CapitalJune 8, 2022 | msn.comTrading was temporarily halted for "ATRS" at 07:05 PM with a stated reason of "News pending."May 24, 2022 | marketbeat.comHalozyme: Antares Pharma Bolsters Growth ProspectsMay 19, 2022 | seekingalpha.comMiMedx Group and Inozyme Stock See Action From Activist InvestorsMay 6, 2022 | finance.yahoo.comHALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMAApril 26, 2022 | finance.yahoo.comLooking Into Antares Pharma Inc's Recent Short InterestApril 14, 2022 | benzinga.comAntares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?April 14, 2022 | finance.yahoo.comAntares Pharma to be acquired by Halozyme in $960M dealApril 13, 2022 | finance.yahoo.comWhy Is Antares Pharma (ATRS) Stock Up Today?April 13, 2022 | investorplace.comAntares Pharma stock rockets after Halozyme buyout deal for a near-50% premiumApril 13, 2022 | morningstar.comWhy Antares Pharma Stock Is Bolting Higher TodayApril 13, 2022 | fool.comAntares Pharma Announces FDA Approval Of TLANDO(TM), an Oral Treatment for Testosterone Replacement TherapyMarch 29, 2022 | stockhouse.comThe Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For AkebiaMarch 29, 2022 | msn.comAntares wins full FDA approval for testosterone replacement therapyMarch 29, 2022 | seekingalpha.comAntares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement TherapyMarch 29, 2022 | finance.yahoo.comAntares Pharma's Return On Capital Employed OverviewMarch 8, 2022 | benzinga.comAntares Pharma (ATRS) Investor Presentation - SlideshowMarch 8, 2022 | seekingalpha.comZacks Investment Research Upgrades Antares Pharma (NASDAQ:ATRS) to HoldZacks Investment Research upgraded Antares Pharma from a "sell" rating to a "hold" rating in a research report on Monday.March 7, 2022 | marketbeat.comAntares Pharma: Q4 Earnings SnapshotMarch 3, 2022 | apnews.comAntares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating ResultsMarch 3, 2022 | finance.yahoo.comAntares Pharma (ATRS) Surpasses Q4 Earnings and Revenue EstimatesMarch 3, 2022 | finance.yahoo.comSmileDirectClub (SDC) Reports Q4 Loss, Lags Revenue EstimatesFebruary 28, 2022 | finance.yahoo.comAntares Pharma to Present at the Cowen 42nd Annual Healthcare ConferenceFebruary 28, 2022 | finance.yahoo.comAntares Pharma (NASDAQ:ATRS) Could Easily Take On More DebtFebruary 18, 2022 | finance.yahoo.comHenry Schein (HSIC) Q4 Earnings and Revenues Beat EstimatesFebruary 15, 2022 | finance.yahoo.comHere's Why I Think Antares Pharma (NASDAQ:ATRS) Might Deserve Your Attention TodayJanuary 13, 2022 | nasdaq.comAntares Pharma, Inc.'s (NASDAQ:ATRS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?January 13, 2022 | finance.yahoo.comAntares Pharma Appoints Claude E. Richardson as Senior Vice President of Human ResourcesJanuary 12, 2022 | finance.yahoo.comAntares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis RescueJanuary 11, 2022 | finance.yahoo.comMedMira strengthen its Board with New AppointmentDecember 17, 2021 | finance.yahoo.comAssertio Shares Gain After Buying Antares' Rheumatoid Arthritis Treatment For $44MDecember 16, 2021 | markets.businessinsider.comIf You Like EPS Growth Then Check Out Antares Pharma (NASDAQ:ATRS) Before It's Too LateDecember 8, 2021 | finance.yahoo.com Get Antares Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov ATRS Media Mentions By Week ATRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATRS News Sentiment▼0.000.56▲Average Medical News Sentiment ATRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATRS Articles This Week▼00▲ATRS Articles Average Week Get Antares Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANGO News ARAY News CTSO News VAPO News XRAY News NEOG News QDEL News STAA News CERS News OSUR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATRS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antares Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antares Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATRS Stock Alerts